Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance

Plasma concentrations of amino acids (AAs), in particular, branched chain AAs (BCAAs), are often found increased in nonalcoholic fatty liver disease (NAFLD); however, if this is due to increased muscular protein catabolism, obesity, and/or increased insulin resistance (IR) or impaired tissue metabolism is unknown. Thus, we evaluated a) if subjects with NAFLD without obesity (NAFLD‐NO) compared to those with obesity (NAFLD‐Ob) display altered plasma AAs compared to controls (CTs); and b) if AA concentrations are associated with IR and liver histology. Glutamic acid, serine, and glycine concentrations are known to be altered in NAFLD. Because these AAs are involved in glutathione synthesis, we hypothesized they might be related to the severity of NAFLD. We therefore measured the AA profile of 44 subjects with NAFLD without diabetes and who had a liver biopsy (29 NAFLD‐NO and 15 NAFLD‐Ob) and 20 CTs without obesity, by gas chromatography–mass spectrometry, homeostasis model assessment of insulin resistance, hepatic IR (Hep‐IR; Hep‐IR = endogenous glucose production × insulin), and the new glutamate–serine–glycine (GSG) index (glutamate/[serine + glycine]) and tested for an association with liver histology. Most AAs were increased only in NAFLD‐Ob subjects. Only alanine, glutamate, isoleucine, and valine, but not leucine, were increased in NAFLD‐NO subjects compared to CTs. Glutamate, tyrosine, and the GSG‐index were correlated with Hep‐IR. The GSG‐index correlated with liver enzymes, in particular, gamma‐glutamyltransferase (R = 0.70), independent of body mass index. Ballooning and/or inflammation at liver biopsy were associated with increased plasma BCAAs and aromatic AAs and were mildly associated with the GSG‐index, while only the new GSG‐index was able to discriminate fibrosis F3‐4 from F0‐2 in this cohort. Conclusion: Increased plasma AA concentrations were observed mainly in subjects with obesity and NAFLD, likely as a consequence of increased IR and protein catabolism. The GSG‐index is a possible marker of severity of liver disease independent of body mass index. (Hepatology 2018;67:145‐158).

[1]  Jens Nielsen,et al.  Personal model‐assisted identification of NAD+ and glutathione metabolism as intervention target in NAFLD , 2017, Molecular systems biology.

[2]  G. Marchesini,et al.  Sarcopenia is associated with severe liver fibrosis in patients with non‐alcoholic fatty liver disease , 2017, Alimentary pharmacology & therapeutics.

[3]  E. Kang,et al.  Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008‐2011) , 2016, Hepatology.

[4]  E. Ruppin,et al.  Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease , 2016, Nature Communications.

[5]  A. Gastaldelli,et al.  Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease , 2016, Hepatology.

[6]  European Association for the Study of the Liver,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease , 2016, Obesity Facts.

[7]  K. Cusi,et al.  Cross-talk between branched-chain amino acids and hepatic mitochondria is compromised in nonalcoholic fatty liver disease. , 2015, American journal of physiology. Endocrinology and metabolism.

[8]  Y. Chiba,et al.  Tyrosine levels are associated with insulin resistance in patients with nonalcoholic fatty liver disease , 2015, Hepatic medicine : evidence and research.

[9]  M. Carstensen,et al.  Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. , 2015, Cell metabolism.

[10]  Nicholette D. Palmer,et al.  Metabolomic profile associated with insulin resistance and conversion to diabetes in the Insulin Resistance Atherosclerosis Study. , 2015, The Journal of clinical endocrinology and metabolism.

[11]  N. Araníbar,et al.  Branched chain amino acid metabolism profiles in progressive human nonalcoholic fatty liver disease , 2014, Amino Acids.

[12]  C. Lynch,et al.  Branched-chain amino acids in metabolic signalling and insulin resistance , 2014, Nature Reviews Endocrinology.

[13]  H. Yki-Järvinen.  Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. , 2014, The lancet. Diabetes & endocrinology.

[14]  M. Uhlén,et al.  Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease , 2014, Nature Communications.

[15]  K. Cusi,et al.  High Prevalence of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels. , 2014, The Journal of clinical endocrinology and metabolism.

[16]  A. Zell,et al.  Circulating Lysophosphatidylcholines Are Markers of a Metabolically Benign Nonalcoholic Fatty Liver , 2013, Diabetes Care.

[17]  G. Targher,et al.  Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis , 2013, Nature Reviews Gastroenterology &Hepatology.

[18]  R. DeFronzo,et al.  Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease , 2013, Nutrients.

[19]  Gabi Kastenmüller,et al.  Early Metabolic Markers of the Development of Dysglycemia and Type 2 Diabetes and Their Physiological Significance , 2013, Diabetes.

[20]  A. Peters,et al.  Identification of Serum Metabolites Associated With Risk of Type 2 Diabetes Using a Targeted Metabolomic Approach , 2013, Diabetes.

[21]  Christian Gieger,et al.  Novel biomarkers for pre-diabetes identified by metabolomics , 2012, Molecular systems biology.

[22]  S. Sookoian,et al.  Alanine and aspartate aminotransferase and glutamine-cycling pathway: their roles in pathogenesis of metabolic syndrome. , 2012, World journal of gastroenterology.

[23]  Susan Cheng,et al.  Metabolite Profiling Identifies Pathways Associated With Metabolic Risk in Humans , 2012, Circulation.

[24]  T. Lehtimäki,et al.  Circulating Metabolite Predictors of Glycemia in Middle-Aged Men and Women , 2012, Diabetes Care.

[25]  V. Lushchak,et al.  Glutathione Homeostasis and Functions: Potential Targets for Medical Interventions , 2012, Journal of amino acids.

[26]  J. Calviño,et al.  Insulin resistance and the metabolism of branched-chain amino acids in humans , 2011, Amino Acids.

[27]  S. Adams.  Emerging perspectives on essential amino acid metabolism in obesity and the insulin-resistant state. , 2011, Advances in nutrition.

[28]  M. Milburn,et al.  Plasma metabolomic profile in nonalcoholic fatty liver disease. , 2011, Metabolism: clinical and experimental.

[29]  Andrea Natali,et al.  α-Hydroxybutyrate Is an Early Biomarker of Insulin Resistance and Glucose Intolerance in a Nondiabetic Population , 2010, PloS one.

[30]  M. Matsuda.  Measuring and estimating insulin resistance in clinical and research settings. , 2010, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[31]  L. J. Hardies,et al.  Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis , 2009, Hepatology.

[32]  A. Sanyal,et al.  Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[33]  Svati H Shah,et al.  A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. , 2009, Cell metabolism.

[34]  M. Orešič,et al.  Hepatic Stearoyl-CoA Desaturase (SCD)-1 Activity and Diacylglycerol but Not Ceramide Concentrations Are Increased in the Nonalcoholic Human Fatty Liver , 2009, Diabetes.

[35]  Amalia Gastaldelli,et al.  Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. , 2007, Gastroenterology.

[36]  Peter Lindgren,et al.  Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary , 2007 .

[37]  R. Gougeon,et al.  The greater contribution of gluconeogenesis to glucose production in obesity is related to increased whole-body protein catabolism. , 2006, Diabetes.

[38]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[39]  E. Ferrannini,et al.  Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms , 2005, Diabetologia.

[40]  G. Marchesini,et al.  Impaired insulin-mediated amino acid plasma disappearance in non-alcoholic fatty liver disease: a feature of insulin resistance. , 2002, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[41]  N. Ballatori,et al.  Endogenous glutathione conjugates: occurrence and biological functions. , 1998, Pharmacological reviews.

[42]  L. Groop,et al.  7 Insulin action and substrate competition , 1993 .

[43]  L. Groop,et al.  Insulin action and substrate competition. , 1993, Bailliere's clinical endocrinology and metabolism.

[44]  M D Jensen,et al.  Protein metabolism in obesity: effects of body fat distribution and hyperinsulinemia on leucine turnover. , 1991, The American journal of clinical nutrition.

[45]  M. Maekawa,et al.  Determination of branched-chain amino acids and tyrosine in serum of patients with various hepatic diseases, and its clinical usefulness. , 1989, Clinical chemistry.

[46]  S. Sherlock,et al.  Plasma amino-acid patterns in liver disease. , 1982, Gut.

[47]  R. Moxley,et al.  Effects of brief starvation on muscle amino acid metabolism in nonobese man. , 1976, The Journal of clinical investigation.

[48]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .